These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. TRK inhibitors in TRK fusion-positive cancers. Drilon A Ann Oncol; 2019 Nov; 30 Suppl 8():viii23-viii30. PubMed ID: 32223935 [TBL] [Abstract][Full Text] [Related]
23. Larotrectinib for paediatric solid tumours harbouring NTRK gene fusions: phase 1 results from a multicentre, open-label, phase 1/2 study. Laetsch TW; DuBois SG; Mascarenhas L; Turpin B; Federman N; Albert CM; Nagasubramanian R; Davis JL; Rudzinski E; Feraco AM; Tuch BB; Ebata KT; Reynolds M; Smith S; Cruickshank S; Cox MC; Pappo AS; Hawkins DS Lancet Oncol; 2018 May; 19(5):705-714. PubMed ID: 29606586 [TBL] [Abstract][Full Text] [Related]
24. The landscape and therapeutic relevance of cancer-associated transcript fusions. Yoshihara K; Wang Q; Torres-Garcia W; Zheng S; Vegesna R; Kim H; Verhaak RG Oncogene; 2015 Sep; 34(37):4845-54. PubMed ID: 25500544 [TBL] [Abstract][Full Text] [Related]
25. Development and Clinical Validation of a Large Fusion Gene Panel for Pediatric Cancers. Chang F; Lin F; Cao K; Surrey LF; Aplenc R; Bagatell R; Resnick AC; Santi M; Storm PB; Tasian SK; Waanders AJ; Hunger SP; Li MM J Mol Diagn; 2019 Sep; 21(5):873-883. PubMed ID: 31255796 [TBL] [Abstract][Full Text] [Related]
26. Feasibility and clinical utility of a pan-solid tumor targeted RNA fusion panel: A single center experience. Hindi I; Shen G; Tan Q; Cotzia P; Snuderl M; Feng X; Jour G Exp Mol Pathol; 2020 Jun; 114():104403. PubMed ID: 32061944 [TBL] [Abstract][Full Text] [Related]
27. Larotrectinib, a highly selective tropomyosin receptor kinase (TRK) inhibitor for the treatment of TRK fusion cancer. Federman N; McDermott R Expert Rev Clin Pharmacol; 2019 Oct; 12(10):931-939. PubMed ID: 31469968 [No Abstract] [Full Text] [Related]
28. Evaluating Targeted Next-Generation Sequencing Assays and Reference Materials for NTRK Fusion Detection. Bormann Chung C; Lee J; Barritault M; Bringuier PP; Xu Z; Huang WY; Beharry A; Castillo J; Christiansen J; Lin JC; Sheffield BS J Mol Diagn; 2022 Jan; 24(1):18-32. PubMed ID: 34656759 [TBL] [Abstract][Full Text] [Related]
29. NTRK testing: First results of the QuiP-EQA scheme and a comprehensive map of NTRK fusion variants and their diagnostic coverage by targeted RNA-based NGS assays. Kirchner M; Glade J; Lehmann U; Merkelbach-Bruse S; Hummel M; Lehmann A; Trautmann M; Kumbrink J; Jung A; Dietmaier W; Endris V; Kazdal D; Ploeger C; Evert M; Horst D; Kreipe H; Kirchner T; Wardelmann E; Büttner R; Weichert W; Dietel M; Schirmacher P; Stenzinger A; Pfarr N Genes Chromosomes Cancer; 2020 Aug; 59(8):445-453. PubMed ID: 32319699 [TBL] [Abstract][Full Text] [Related]
37. Activity of Entrectinib in a Patient With the First Reported Sigal D; Tartar M; Xavier M; Bao F; Foley P; Luo D; Christiansen J; Hornby Z; Maneval EC; Multani P J Natl Compr Canc Netw; 2017 Nov; 15(11):1317-1322. PubMed ID: 29118225 [TBL] [Abstract][Full Text] [Related]
38. Evaluating gene fusions in solid tumors - Clinical experience using an RNA based 53 gene next-generation sequencing panel. Selvam P; Kelly K; Hesse AN; Spitzer D; Reddi HV Cancer Genet; 2019 Apr; 233-234():32-42. PubMed ID: 31109592 [TBL] [Abstract][Full Text] [Related]
39. Evidence of NTRK1 Fusion as Resistance Mechanism to EGFR TKI in EGFR+ NSCLC: Results From a Large-Scale Survey of NTRK1 Fusions in Chinese Patients With Lung Cancer. Xia H; Xue X; Ding H; Ou Q; Wu X; Nagasaka M; Shao YW; Hu X; Ou SI Clin Lung Cancer; 2020 May; 21(3):247-254. PubMed ID: 31761448 [TBL] [Abstract][Full Text] [Related]